XOSPATA, generically known as gilteritinib, is a prescription medication specifically designed for the treatment of adult patients who have been diagnosed with relapsed or refractory acute myeloid leukemia (AML) with a FLT3 mutation as detected by an FDA-approved test. As an oral kinase inhibitor, XOSPATA works by targeting and inhibiting the activity of the FLT3 mutations, which are one of the most common genetic abnormalities in AML and are associated with a poor prognosis. By blocking these mutations, XOSPATA can help to slow down or stop the growth of cancer cells. It is important for patients to be tested for the FLT3 mutation to determine if XOSPATA is an appropriate treatment option for their condition.